Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5588799 | 0.80 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL14276103 | 0.74 | PSMB5 (0.36) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3286343 | 0.72 | MEN1 (0.48) | MEN1KMT2ARAPGEF4ALDH1A1 | |
| SCHEMBL3286340 | 0.72 | MEN1 (0.48) | MEN1KMT2ARAPGEF4ALDH1A1 | |
| SCHEMBL6640786 | 0.67 | MEN1 (0.37) | MEN1KMT2ARAPGEF4 | |
| SCHEMBL502928 | 0.66 | RAPGEF4 (0.43) | MEN1KMT2ASMN1; SMN2RAPGEF4ALDH1A1 | |
| SCHEMBL6377762 | 0.64 | RAPGEF4 (0.41) | MEN1KMT2ARAPGEF4ALDH1A1 | |
| SCHEMBL27621238 | 0.64 | F2 (0.38) | MEN1KMT2ARAPGEF4ALDH1A1 | |
| SCHEMBL7026232 | 0.62 | GRIN2D (0.46) | MEN1KMT2ARAPGEF4ALDH1A1 | |
| SCHEMBL9368835 | 0.62 | RAPGEF4 (0.39) | MEN1KMT2ARAPGEF4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998895-B2 | Catalysts for olefin polymerization | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998895-B2 | Catalysts for olefin polymerization | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100222531-A1 | CATALYSTS FOR OLEFIN POLYMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222531-A1 | CATALYSTS FOR OLEFIN POLYMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100029469-A1 | CATALYSTS FOR OLEFIN POLYMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029469-A1 | CATALYSTS FOR OLEFIN POLYMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-02-04 | — | — | US | disclosed |
| US-7439314-B2 | Catalysts for olefin polymerization | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439314-B2 | Catalysts for olefin polymerization | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222531-A1 | CATALYSTS FOR OLEFIN POLYMERIZATION | PORCN, PUF60, CAD | MEN1 883/4885KMT2A 4665/4885SMN1; SMN2 4072/4885 |
| US-20100029469-A1 | CATALYSTS FOR OLEFIN POLYMERIZATION | PORCN, PUF60, CAD | MEN1 883/4885KMT2A 4665/4885SMN1; SMN2 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.